STAAR Surgical Company (STAA) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

Total Cash From Operating Activities Chart for STAAR Surgical Company

STAAR Surgical Company (STAA) operating cash flow for FY2025 was USD -34.2M, a -317.7% change from FY2024. STAAR Surgical Company's operating cash flow moved from USD -100.0K in 1990 to USD -34.2M in 2025 over 35 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.13B
Implied Share Price
$22.61
Enterprise Value
$1.32B
Revenue (TTM)
$339.59M
EBITDA
$49.76M
Profit Margin
1.13%
Trailing P/E
282.62
Forward P/E
126.58
Price/Book (MRQ)
4.11
Price/Sales (TTM)
3.34
EV/EBITDA
89.62
EV/Revenue
4.55
Dividend Yield
—
Book Value
$7.29
Free Cash Flow (FY2025)
-$40.05M
Free Cash Flow Yield
-3.53%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.